File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV

TitlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2006
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6 How to Cite?
Abstract
BACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …
DescriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)
Persistent Identifierhttp://hdl.handle.net/10722/101383
ISSN
2013 Impact Factor: 10.401
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorHan, KHen_HK
dc.contributor.authorYoon, SKen_HK
dc.contributor.authorUm, SHen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorKim, HSen_HK
dc.contributor.authorKim, HRen_HK
dc.contributor.authorChung, HCen_HK
dc.contributor.authorKim, CRen_HK
dc.contributor.authorHsyu, Pen_HK
dc.contributor.authorAverett, Den_HK
dc.contributor.authorWorland, Sen_HK
dc.contributor.authorKim, Jen_HK
dc.date.accessioned2010-09-25T19:47:25Z-
dc.date.available2010-09-25T19:47:25Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6en_HK
dc.identifier.issn0168-8278en_HK
dc.identifier.urihttp://hdl.handle.net/10722/101383-
dc.descriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)-
dc.description.abstractBACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_HK
dc.relation.ispartofJournal of Hepatologyen_HK
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBVen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0168-8278&volume=44, suppl 2, article no. 6&spage=S5&epage=&date=2006&atitle=Phase+II+multi-centre,+dose-escalating+study+of+LB80380+(ANA380)+in+hepatitis+B+patients+with+lamivudine-resistant+YMDD+mutant+HBVen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.doi10.1016/S0168-8278(06)80007-3-
dc.identifier.hkuros129577en_HK
dc.identifier.volume44en_HK
dc.identifier.issuesuppl. 2-
dc.identifier.spageS5en_HK
dc.identifier.epageS5-
dc.identifier.isiWOS:000237328100007-
dc.publisher.placeNetherlands-
dc.description.otherThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats